An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Terminated · Phase 1 · NCT04189614
Conditions: Cancer, Non-small Cell Lung Cancer (NSCLC)
At a glance
- Research payments reported, 2025
- $6,742
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- AbbVie (with Pfizer)
- Tested
- Cofetuzumab Pelidotin (drug)
- Dates
- Started 2020-02-13; completion 2026-05-07
- Results posted
- Not yet
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $6,742 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric S. Schaefer, M.D. Hematology & Oncology · Rogers, AR
- David Camidge, MD Medical Oncology · Aurora, CO
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Highlands Oncology Group PA $5,750
- Regents of the University of Colorado $992
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.